Despite concerns about the efficacy and safety of checkpoint inhibitors, many biotech companies are advancing them in clinical trials to treat cancer. By 2032, the market for these drugs could reach nearly $189.4 billion. While these inhibitors have shown dramatic results in some cancer patients, they only seem to work for a small percentage. As a result, research is shifting towards combining them with other cancer treatments, and exploring potential new inhibitors. These advances are expected to revolutionize cancer care.
News – Masimo reports cyber incident affecting production sites – teiss
Masimo has reported a cyber incident that has impacted its production sites. The company is currently assessing the situation to understand the extent of the
